Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

You have full access to this article via your institution. Molecular glue degraders are small molecules that promote the interaction of a target protein with an E3 ubiquitin ligase to induce ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), shedding light on potential therapeutic targets for combating tumor progression, ...

Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 12.14%, which has investors questioning if this is right time ...